American Society of Hematology

banner image

ASH Meeting on Hematologic Malignancies

Early registration is now open. Hear top experts in hematologic malignancies discuss the latest development in clinical care.

Learn more
banner image

AML Matters Program

Learn how to improve diagnosis and treatment of patients with acute myeloid leukemia (AML). Attend one of four complimentary meetings being held throughout the year.

Learn more
banner image

ASH Choosing Wisely Champions

ASH is now accepting applications for the 2017 ASH Choosing Wisely Champions. The deadline to submit applications is Thursday, June 1, 2017.

Learn more

Support Medical Research

Urge your members of Congress to support continued medical research funding.

Take action
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.

Learn more
  • Medical Groups Unite in Support of Science

    As the world's leading organizations representing clinicians, laboratory researchers, and physician-scientists committed to improving patient care, we support the March for Science and its nonpartisan call for the appreciation of scientific evidence, education, and investment. Science has no political agenda but gives us the tools to find the truths about our world and then implement informed policies to enrich our communities.

  • ASH Awards $750k to Preserve Promising Biomedical Research

    In 2012, the American Society of Hematology (ASH) committed to preserving blood disease research threatened by federal budget cuts to the National Institutes of Health (NIH) by establishing the ASH Bridge Grant Program. Today, ASH announced the names of five investigators whose research has been awarded $150,000 as part of the eighth round of ASH Bridge Grants.

  • Anticoagulant Apixaban Superior to Warfarin for Reducing Brain Bleeds in Patients with Atrial Fibrillation

    In a new analysis, patients with atrial fibrillation showed a substantially reduced risk of dangerous bleeding in the brain, known as intracranial hemorrhage, when taking the newer anticoagulant apixaban compared to those taking warfarin. The study also showed that taking aspirin increased the risk of intracranial hemorrhage, especially in older patients.

  • American Society of Hematology Announces 2017 Translational Research Training in Hematology Program Participants

    The American Society of Hematology and the European Hematology Association have announced the names of 20 early-career hematologists who will participate in the joint 2017 Translational Research Training in Hematology program.

View all press releases
  • ACA Update

    The House of Representatives released legislation, titled the “American Health Care Act,” to repeal the Affordable Care Act.  As written, ASH has serious concerns that this legislation will reduce overall access to coverage and treatment and would greatly impact patients with hematologic diseases and disorders.

  • DEA Eliminates Grace Period for Registration Renewal

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. 

  • CMS Announces End to Medicare Part B Drug Payment Model

    On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model.  CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.

  • NHLBI Small Business Innovation Research Funding Opportunity Fosters Production of Blood Cells From Stem Cells

    ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.

View all policy news
  • Letter to the Editor: In Response to Hematology...Literally and Seriously

    Dr. Rosenblum responds to The Hematologist Editor-in-Chief's commentary in the Year's Best issue.

  • Planting Evidence

    Review the peripheral blood smear to determine the diagnosis of a 31-year-old man referred to hematology clinic for evaluation of long-standing thrombocytopenia.

  • When More (Oxygen) Is Not Better

    Take the challenge to learn what test is most likely to yield the diagnosis for a case of a 58-year-old Asian woman with history of inclusion body myositis on high-dose corticosteroids and methotrexate, noted to be hypoxic.

  • Blasts of a Different Sort

    Can you tell what the diagnosis is for a man with a history of recurrent necrotizing pancreatitis and end-stage renal disease on intermittent hemodialysis by looking at his bone marrow biopsy?

View all Hematologist articles